After finishing at $35.67 in the prior trading day, Progyny Inc (NASDAQ: PGNY) closed at $35.75, up 0.22%. In other words, the price has increased by $+0.08 from its previous closing price. On the day, 900859 shares were traded.
Ratios:
Our goal is to gain a better understanding of PGNY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.63. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $49.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $48.
On September 27, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $46.Canaccord Genuity initiated its Buy rating on September 27, 2023, with a $46 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 23 ’24 when Payson Norman sold 200 shares for $56.29 per share. The transaction valued at 11,258 led to the insider holds 580,656 shares of the business.
Livingston Mark S. sold 11,165 shares of PGNY for $419,979 on Apr 01 ’24. The CHIEF FINANCIAL OFFICER now owns 50,119 shares after completing the transaction at $37.62 per share. On Apr 01 ’24, another insider, Sturmer Michael E, who serves as the PRESIDENT of the company, sold 6,395 shares for $37.60 each. As a result, the insider received 240,452 and left with 384,553 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 3.44B and an Enterprise Value of 3.09B. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 57.96, and their Forward P/E ratio for the next fiscal year is 36.02. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.17 while its Price-to-Book (P/B) ratio in mrq is 6.18. Its current Enterprise Value per Revenue stands at 2.84 whereas that against EBITDA is 47.94.
Stock Price History:
Over the past 52 weeks, PGNY has reached a high of $44.95, while it has fallen to a 52-week low of $29.44. The 50-Day Moving Average of the stock is 37.76, while the 200-Day Moving Average is calculated to be 36.44.
Shares Statistics:
The stock has traded on average 819.47K shares per day over the past 3-months and 785.64k shares per day over the last 10 days, according to various share statistics. A total of 95.73M shares are outstanding, with a floating share count of 83.26M. Insiders hold about 13.72% of the company’s shares, while institutions hold 87.03% stake in the company. Shares short for PGNY as of Mar 15, 2024 were 6.2M with a Short Ratio of 7.57, compared to 6.55M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.43% and a Short% of Float of 7.82%.
Earnings Estimates
Its stock is currently analyzed by 9 different market analysts. On average, analysts expect EPS of $0.13 for the current quarter, with a high estimate of $0.18 and a low estimate of $0.12, while EPS last year was $0.18. The consensus estimate for the next quarter is $0.18, with high estimates of $0.21 and low estimates of $0.15.
Analysts are recommending an EPS of between $0.84 and $0.64 for the fiscal current year, implying an average EPS of $0.7. EPS for the following year is $1, with 10 analysts recommending between $1.27 and $0.79.
Revenue Estimates
9 analysts predict $289.46M in revenue for the current quarter. It ranges from a high estimate of $291.2M to a low estimate of $287M. As of the current estimate, Progyny Inc’s year-ago sales were $258.39M, an estimated increase of 12.00% from the year-ago figure.
A total of 10 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.31B, while the lowest revenue estimate was $1.29B, resulting in an average revenue estimate of $1.3B. In the same quarter a year ago, actual revenue was $1.09B, up 19.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $1.56B in the next fiscal year. The high estimate is $1.6B and the low estimate is $1.53B. The average revenue growth estimate for next year is up 20.20% from the average revenue estimate for this year.
